Meso Scale Diagnostics LLC

Meso Scale Diagnostics LLC, doing business as Meso Scale Discovery, is a Native American-owned small business manufacturer of electrochemiluminescence-based immunoassay instruments, multiplex assay kits, and related diagnostic reagents that operates as a prime contractor (99% of awards) across defense, health research, and biodefense missions. The company competes full-and-open without reliance on socioeconomic set-asides, holding a for-profit limited liability company structure headquartered in Rockville, Maryland, with primary NAICS concentrations in analytical laboratory instrument manufacturing (385 awards) and in-vitro diagnostic substance manufacturing (281 awards).

Meso Scale Discovery's core capability portfolio centers on electrochemiluminescence (ECL) detection platforms and multiplex biomarker assay development. Representative work spans a $23.2 million time-and-materials contract from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response for COVID-19 vaccine development assays (awarded September 2023, ultimate completion September 2026); a $7.95 million single-award indefinite delivery contract with the Joint Program Executive Office for Chemical and Biological Defense for manufacturing biodefense and performance qualification kits (awarded June 2026, expiring June 2031); a $25 million single-award IDC with the Defense Logistics Agency Medical Supply Chain for multiplex assay kits, plate readers, and consumables (awarded June 2024, expiring June 2029); and a $2.28 million single-award IDC with the Defense Health Agency for reagents, consumables, and equipment (awarded August 2023, expiring August 2029). Concrete product lines include the MESO QuickPlex SQ 120MM plate reader system, V-PLEX and U-PLEX multiplex assay kits targeting cytokine and biomarker panels, SECTOR imaging platforms, and assay development services for infectious disease and clinical biomarker applications.

Customer concentration is highly skewed toward federal health and defense agencies but the dollar value is dominated by a single customer. The National Institute of Allergy and Infectious Diseases leads by award count at 172 awards carrying $21.6 million combined potential value, but the Department of the Army Acquisition Support Center Joint Program Executive Office for Chemical and Biological Defense anchors 99% of combined potential value across all awards, holding 31 awards valued at $8.33 billion—a reflection of large indefinite delivery contract ceilings. The Centers for Disease Control and Prevention (22 awards, $26 million), the Defense Logistics Agency Medical Supply Chain (28 awards, $25.5 million), and the U.S. Secret Service (20 awards, $19.8 million) represent the secondary tier of customer relationships. Seventy-four distinct federal agencies have issued awards, indicating broad market penetration but shallow concentration outside the top five.

Meso Scale Discovery holds parent contract vehicles on three prime indefinite delivery contracts: the Joint PEO Chemical and Biological Defense $7.95 million IDC (31 awards issued through June 2031), the DLA Medical Supply Chain $25 million IDC (28 awards issued through June 2029), and the Defense Health Agency $2.28 million IDC (20 awards issued through August 2029). Additional smaller vehicles include Army BPAs and blanket purchase agreements. Task orders issued under these vehicles range from $1 thousand to $409 thousand, with delivery orders representing the majority of vehicle activity. The vendor competes full-and-open on these vehicles without set-aside restrictions.

Activity has declined from a peak of 70 awards in 2023 to 23 awards in both 2025 and 2026 year-to-date, suggesting maturation of vaccine and pandemic-related spending post-COVID-19 and a shift toward sustainment rather than new program awards. Twelve awards carrying combined potential value of $806 thousand complete within the next twenty-four months, presenting modest recompete exposure concentrated in maintenance and service contracts. The vendor operates as a pure prime across its federal footprint—99% of awards are prime contracts and IDVs with only 7 named grant sub-awards (1% of total awards). SCI-reportable invoiced revenue was $36 thousand in FY2022, $0 in FY2023 and FY2024, and $8.9 million in FY2025, showing recent scaling in service contract activity; the company reported 1.5 FTEs on SCI records in FY2025. Government-paid hourly rates on SCI service contracts cluster at a median of $217.66/hr across the available records, reflecting senior technical labor. The vendor builds its own delivery teams rather than subcontracting—zero sub-hours share is reported across SCI prime contracts.

Meso Scale Discovery also holds federal grant positions as a prime recipient and sub-recipient. The company received $997,807 from the Defense Health Agency (CFDA 12.420, Military Medical Research and Development) for development of ultrasensitive immunoassays for TDP-43 pathology in amyotrophic lateral sclerosis (awarded July 2026, completion June 2028); $704,431.23 from the Defense Health Agency for ALS clinical trial immunoassay development (September 2023 through August 2025, completed); a cooperative agreement from the National Institute of Allergy and Infectious Diseases for flexible high-throughput influenza vaccine immunological assays (awarded May 2023, completion April 2026); and a project grant from the National Institute of Diabetes and Digestive and Kidney Diseases for extracellular vesicle biomarker detection platforms for type 1 diabetes (awarded September 2022, completion May 2027). As a sub-recipient, the vendor has partnered on University of California Irvine R01 grants for tuberculosis biomarker assay optimization (CFDA unspecified, with George Sigal as co-investigator directing MSD work on M. tuberculosis protein detection), Arizona State University cancer biomarker discovery projects, and The Geneva Foundation multiplex malaria diagnostics platform development. This grant footprint underscores the vendor's role as a specialized technology provider in biodefense and infectious disease research rather than as a primary investigator.